Li, Z., Zheng, Q., Yang, K., Wang, X., Li, J., Fei, Q., Zhai, J., Ming, Z., Wen, X., Song, Y., Zhao, Y., Wang, L., Wu, T. (2026). Pre-transplant MRD negativity and TP53 mutation status determine survival after CAR-T therapy bridged to allo-HSCT for refractory/relapse B-ALL.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6556